Meeting Coverage > > SABCS– Triplet treatment might go beyond advantages of present “quite active doublet” treatment, professional states
by Wayne Kuznar, Contributing Writer December 10, 2023
SAN ANTONIO– The addition of inavolisib to palbociclib (Ibrance) plus fulvestrant (Faslodex) improved progression-free survival (PFS) in clients with frequent PIK3CA-altered HR-positive, HER2-negative innovative breast cancer, according to the INAVO120 trial.
In clients who repeated within 12 months of adjuvant endocrine treatment, treatment with the investigational selective PI3Kα inhibitor showed more than a doubling of average PFS from 7.3 to 15 months (stratified HR 0.43, P< 0.0001), reported Komal Jhaveri, MD, of Memorial Sloan Kettering Cancer Center in New York City.
There likewise was a pattern towards enhanced general survival (OS) at the very first interim analysis (average follow-up of 21.3 months) with inavolisib compared to placebo as add-on treatment, she stated at a San Antonio Breast Cancer Symposium (SABCS) press rundown.
Jhaveri mentioned that the triplet treatment “might represent a brand-new requirement of look after clients with PIK3CA-altered HR-positive, HER2-negative sophisticated breast cancer. What we have actually discovered up until now is that we have actually not had the ability to integrate alpelisib with a CDK4/6 inhibitor,